Laurus Labs to invest up to €9.8M in JV KRKA Pharma for capex

Laurus Labs' Board approved an investment of up to EURO 9.8 million in its joint venture, KRKA Pharma Private Limited. Co-venturer KRKA d.d., Novo mesto, Slovenia, will also invest approximately EURO 10.2 million. The existing 51:49 shareholding ratio between KRKA d.d. and Laurus Labs will remain unchanged. This strategic investment will fund KRKA's capital expenditure plan for setting up a new manufacturing facility. The transaction is classified as a related party transaction, conducted on an arm's length basis. KRKA Pharma, incorporated in April 2024, is in the pharmaceutical industry and reported a turnover of INR 10.47 million for 2025-26. The investment is expected to be completed in FY2026-27.